{"transactions":[{"id":728819,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"DUNCAN BARBARA GAYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T21:00:09.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":37700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":37700,"derivative":{"exercise_price":4.36,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":37700},"source":{"system":"sec-edgar","filing":"0001193125-26-279721","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000119312526279721/ownership.xml","form_type":"4"}},{"id":728818,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"DUNCAN BARBARA GAYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-23T21:00:09.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":26700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":26700,"derivative":{"underlying":"Common Stock","underlying_shares":26700},"source":{"system":"sec-edgar","filing":"0001193125-26-279721","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000119312526279721/ownership.xml","form_type":"4"}},{"id":728817,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"DUNCAN BARBARA GAYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-23T21:00:09.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":29600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested in full on June 18, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested in full on June 18, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":29600},"source":{"system":"sec-edgar","filing":"0001193125-26-279721","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000119312526279721/ownership.xml","form_type":"4"}},{"id":728816,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"DUNCAN BARBARA GAYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-23T21:00:09.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":29600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":92350,"source":{"system":"sec-edgar","filing":"0001193125-26-279721","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000119312526279721/ownership.xml","form_type":"4"}},{"id":788722,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"DUNCAN BARBARA GAYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2026-05-07T23:02:11.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":6040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":6040,"derivative":{"exercise_price":65.87,"expiration_date":"2036-05-05","underlying":"Common Stock","underlying_shares":6040},"source":{"system":"sec-edgar","filing":"0001159036-26-000060","document":"wk-form4_1778194928.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000060/wk-form4_1778194928.xml","form_type":"4"}},{"id":788721,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"DUNCAN BARBARA GAYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-07T23:02:11.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":3796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director."}],"balance_after":23715,"source":{"system":"sec-edgar","filing":"0001159036-26-000060","document":"wk-form4_1778194928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000060/wk-form4_1778194928.xml","form_type":"4"}},{"id":873847,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"DUNCAN BARBARA GAYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-02T21:30:14.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":1.65,"expiration_date":"2036-02-25","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001353128-26-000002","document":"form4-03022026_040309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000135312826000002/form4-03022026_040309.xml","form_type":"4"}},{"id":1102576,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-24T22:05:09.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":29600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested in full on June 20, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested in full on June 20, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":29600},"source":{"system":"sec-edgar","filing":"0000950170-25-089609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000095017025089609/ownership.xml","form_type":"4"}},{"id":1102575,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-24T22:05:09.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":41200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 20, 2025, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":41200,"derivative":{"exercise_price":3.25,"expiration_date":"2035-06-19","underlying":"Common Stock","underlying_shares":41200},"source":{"system":"sec-edgar","filing":"0000950170-25-089609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000095017025089609/ownership.xml","form_type":"4"}},{"id":1102574,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-24T22:05:09.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":29600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":29600,"derivative":{"underlying":"Common Stock","underlying_shares":29600},"source":{"system":"sec-edgar","filing":"0000950170-25-089609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000095017025089609/ownership.xml","form_type":"4"}},{"id":1102573,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T22:05:09.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":true,"shares":29600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":62750,"source":{"system":"sec-edgar","filing":"0000950170-25-089609","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000095017025089609/ownership.xml","form_type":"4"}},{"id":1106133,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T20:45:07.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":0.57,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001415889-25-017696","document":"form4-06182025_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000141588925017696/form4-06182025_040603.xml","form_type":"4"}},{"id":1161474,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2025-05-02T20:04:53.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents annual stock option grant under the Issuer's director compensation program.  This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":5750,"derivative":{"exercise_price":60.03,"expiration_date":"2035-05-01","underlying":"Common Stock","underlying_shares":5750},"source":{"system":"sec-edgar","filing":"0001415889-25-011769","document":"form4-05022025_080549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925011769/form4-05022025_080549.xml","form_type":"4"}},{"id":1161473,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-02T20:04:53.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":4165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program.  Each RSU represents the right to receive one share of common stock of the Issuer.  This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders.  These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director."}],"balance_after":19919,"source":{"system":"sec-edgar","filing":"0001415889-25-011769","document":"form4-05022025_080549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925011769/form4-05022025_080549.xml","form_type":"4"}},{"id":1330686,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-16T21:15:16.000Z","date":"2024-12-12","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares will vest in 36 equal monthly installments, subject to the Reporting Person's continued services through such date."}],"balance_after":90000,"derivative":{"exercise_price":1.06,"expiration_date":"2034-12-11","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001415889-24-029472","document":"form4-12162024_041213.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000141588924029472/form4-12162024_041213.xml","form_type":"4"}},{"id":1471913,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T22:12:53.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":41200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 21, 2024, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":41200,"derivative":{"exercise_price":3.44,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":41200},"source":{"system":"sec-edgar","filing":"0000950170-24-076400","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000095017024076400/ownership.xml","form_type":"4"}},{"id":1471912,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-21T22:12:53.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":29600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":29600,"derivative":{"underlying":"Common Stock","underlying_shares":29600},"source":{"system":"sec-edgar","filing":"0000950170-24-076400","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000095017024076400/ownership.xml","form_type":"4"}},{"id":1475047,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-18T21:00:07.000Z","date":"2024-06-16","kind":"exercise","planned":false,"acquired":false,"shares":33150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units are fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units do not have an expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":33150},"source":{"system":"sec-edgar","filing":"0000950170-24-074985","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000095017024074985/ownership.xml","form_type":"4"}},{"id":1475046,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-18T21:00:07.000Z","date":"2024-06-16","kind":"exercise","planned":false,"acquired":true,"shares":33150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":33150,"source":{"system":"sec-edgar","filing":"0000950170-24-074985","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000095017024074985/ownership.xml","form_type":"4"}},{"id":1492526,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:22:17.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":4.64,"underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0000950170-24-068885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068885/ownership.xml","form_type":"4"}},{"id":1492525,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:22:17.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":3.6,"underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0000950170-24-068885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068885/ownership.xml","form_type":"4"}},{"id":1492524,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:22:17.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":8.15,"underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0000950170-24-068885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068885/ownership.xml","form_type":"4"}},{"id":1492523,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:22:17.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the \"Arrangement Agreement\"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden (\"Parent\") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act (\"Purchaser\"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the \"Shares\") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the \"Effective Time\"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the \"Cash Consideration\") plus (ii) one contingent value right (each, a \"CVR\") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":12.4,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-068885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068885/ownership.xml","form_type":"4"}},{"id":1533928,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2024-04-29T21:54:20.000Z","date":"2024-04-25","kind":"grant","planned":false,"acquired":true,"shares":8804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents annual stock option grant under the Issuer's director compensation program.  This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":8804,"derivative":{"exercise_price":38.46,"expiration_date":"2034-04-25","underlying":"Common Stock","underlying_shares":8804},"source":{"system":"sec-edgar","filing":"0001415889-24-011681","document":"form4-04292024_090415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924011681/form4-04292024_090415.xml","form_type":"4"}},{"id":1533927,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-29T21:54:20.000Z","date":"2024-04-25","kind":"grant","planned":false,"acquired":true,"shares":6501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program.  Each RSU represents the right to receive one share of common stock of the Issuer.  This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders.  These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director."}],"balance_after":15754,"source":{"system":"sec-edgar","filing":"0001415889-24-011681","document":"form4-04292024_090415.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924011681/form4-04292024_090415.xml","form_type":"4"}},{"id":1619053,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-26T22:54:34.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 22, 2025, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-24-003958","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919124003958/doc4.xml","form_type":"4"}},{"id":1847694,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-21T20:05:15.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":46750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 16, 2023, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":46750,"derivative":{"exercise_price":4.12,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":46750},"source":{"system":"sec-edgar","filing":"0000899243-23-016127","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000089924323016127/doc4.xml","form_type":"4"}},{"id":1847693,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-21T20:05:15.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":33150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":33150,"derivative":{"underlying":"Common Stock","underlying_shares":33150},"source":{"system":"sec-edgar","filing":"0000899243-23-016127","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000089924323016127/doc4.xml","form_type":"4"}},{"id":1856002,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Opion (Right to Buy)","published_at":"2023-06-14T17:06:49.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 14, 2024 or (ii) the 2024 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":4.64,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-23-037091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919123037091/doc4.xml","form_type":"4"}},{"id":1899762,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-05-09T22:16:24.000Z","date":"2023-05-05","kind":"grant","planned":false,"acquired":true,"shares":11371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents annual stock option grant under the Issuer's director compensation program.  This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":11371,"derivative":{"exercise_price":31,"exercise_date":"2024-05-05","expiration_date":"2033-05-05","underlying":"Common Stock","underlying_shares":11371},"source":{"system":"sec-edgar","filing":"0001415889-23-007690","document":"form4-05092023_100516.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923007690/form4-05092023_100516.xml","form_type":"4"}},{"id":1899761,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-09T22:16:24.000Z","date":"2023-05-05","kind":"grant","planned":false,"acquired":true,"shares":8065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program.  Each RSU represents the right to receive one share of common stock of the Issuer.  This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders.  These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director."}],"balance_after":9253,"source":{"system":"sec-edgar","filing":"0001415889-23-007690","document":"form4-05092023_100516.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923007690/form4-05092023_100516.xml","form_type":"4"}},{"id":1904427,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:41.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":2.8,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001640455-23-000108","document":"wf-form4_168320060992986.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000108/wf-form4_168320060992986.xml","form_type":"4"}},{"id":1904426,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:41.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":7.27,"underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-23-000108","document":"wf-form4_168320060992986.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000108/wf-form4_168320060992986.xml","form_type":"4"}},{"id":1904425,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:41.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":7.58,"underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-23-000108","document":"wf-form4_168320060992986.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000108/wf-form4_168320060992986.xml","form_type":"4"}},{"id":1904424,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:41.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":4.46,"underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-23-000108","document":"wf-form4_168320060992986.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000108/wf-form4_168320060992986.xml","form_type":"4"}},{"id":1904423,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:41.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13550,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":7.92,"underlying":"Common Stock","underlying_shares":13550},"source":{"system":"sec-edgar","filing":"0001640455-23-000108","document":"wf-form4_168320060992986.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000108/wf-form4_168320060992986.xml","form_type":"4"}},{"id":1904422,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:41.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10840,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":9.56,"underlying":"Common Stock","underlying_shares":10840},"source":{"system":"sec-edgar","filing":"0001640455-23-000108","document":"wf-form4_168320060992986.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000108/wf-form4_168320060992986.xml","form_type":"4"}},{"id":1904421,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:41.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34271,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent (\"Merger Sub\"), dated as of March 26, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 3, 2023 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":4.21,"underlying":"Common Stock","underlying_shares":34271},"source":{"system":"sec-edgar","filing":"0001640455-23-000108","document":"wf-form4_168320060992986.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000108/wf-form4_168320060992986.xml","form_type":"4"}},{"id":1990047,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-27T21:47:09.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 23, 2024 subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.5,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-013207","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919123013207/doc4.xml","form_type":"4"}},{"id":2028918,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-07T21:06:19.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":1188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted under the Issuer's director compensation program.  Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's 2023 annual meeting of stockholders.  These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director."}],"balance_after":1188,"source":{"system":"sec-edgar","filing":"0001415889-23-002070","document":"form4-02072023_090211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002070/form4-02072023_090211.xml","form_type":"4"}},{"id":2217053,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-07-01T21:01:14.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":500000,"derivative":{"exercise_price":0.28,"exercise_date":"2023-07-01","expiration_date":"2032-07-01","underlying":"Ordinary Shares","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001104659-22-076895","document":"tm2220260-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000110465922076895/tm2220260-2_4seq1.xml","form_type":"4"}},{"id":2220129,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-28T21:02:17.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2023 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":20000,"derivative":{"exercise_price":2.8,"expiration_date":"2032-06-24","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001640455-22-000069","document":"wf-form4_165646451016548.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045522000069/wf-form4_165646451016548.xml","form_type":"4"}},{"id":2224268,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Opion (Right to Buy)","published_at":"2022-06-22T19:07:42.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 14, 2023 or (ii) the 2023 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":3.6,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-22-038769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919122038769/doc4.xml","form_type":"4"}},{"id":2225292,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-21T23:49:41.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":61264,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in twelve (12) equal monthly installments following June 17, 2022, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":61264,"derivative":{"exercise_price":6.5,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":61264},"source":{"system":"sec-edgar","filing":"0000899243-22-023505","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000089924322023505/doc4.xml","form_type":"4"}},{"id":2298296,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-12T20:55:36.000Z","date":"2022-04-08","kind":"grant","acquired":true,"shares":21347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21347,"derivative":{"exercise_price":3.22,"expiration_date":"2032-04-07","underlying":"Common Stock","underlying_shares":21347},"source":{"system":"sec-edgar","filing":"0001209191-22-024163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919122024163/doc4.xml","form_type":"4"}},{"id":2411554,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-05T01:48:56.000Z","date":"2022-02-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 3, 2023 subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.72,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-007326","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919122007326/doc4.xml","form_type":"4"}},{"id":2644200,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2021-07-02T21:00:49.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":379788,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":379788,"derivative":{"exercise_price":0.71,"exercise_date":"2022-07-01","expiration_date":"2031-07-01","underlying":"Ordinary Shares","underlying_shares":379788},"source":{"system":"sec-edgar","filing":"0001104659-21-088960","document":"tm2121284-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000110465921088960/tm2121284-1_4seq1.xml","form_type":"4"}},{"id":2658795,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-22T16:45:43.000Z","date":"2021-06-18","kind":"grant","acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2022 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":15700,"derivative":{"exercise_price":7.27,"expiration_date":"2031-06-18","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-21-000110","document":"wf-form4_162439469478970.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000110/wf-form4_162439469478970.xml","form_type":"4"}},{"id":2660697,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T21:35:15.000Z","date":"2021-06-18","kind":"grant","acquired":true,"shares":34025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in twelve (12) equal monthly installments following June 18, 2021, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":34025,"derivative":{"exercise_price":23.39,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":34025},"source":{"system":"sec-edgar","filing":"0000899243-21-025045","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000089924321025045/doc4.xml","form_type":"4"}},{"id":2671696,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-12T00:31:46.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on June 11, 2022 subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":4.49,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-040081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919121040081/doc4.xml","form_type":"4"}},{"id":2679490,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Opion (Right to Buy)","published_at":"2021-06-07T16:14:28.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 4, 2022 or (ii) the 2022 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":8.15,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-21-038570","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919121038570/doc4.xml","form_type":"4"}},{"id":2707668,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-19T00:57:18.000Z","date":"2021-05-17","kind":"grant","acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on June 5, 2021, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":1750,"derivative":{"exercise_price":3.67,"expiration_date":"2031-05-16","underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001209191-21-033828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919121033828/doc4.xml","form_type":"4"}},{"id":2994967,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-03T16:56:39.000Z","date":"2020-10-30","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 36 substantially equal monthly installments starting on November 30, 2020."}],"balance_after":30000,"derivative":{"exercise_price":12.4,"expiration_date":"2030-10-29","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-20-030257","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320030257/doc4.xml","form_type":"4"}},{"id":2997397,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-30T21:49:09.000Z","date":"2020-10-29","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 36 equal monthly installments following October 29, 2020."}],"balance_after":80000,"derivative":{"exercise_price":24,"expiration_date":"2030-10-28","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-20-029960","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000089924320029960/doc4.xml","form_type":"4"}},{"id":3001137,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2020-10-23T17:32:04.000Z","date":"2020-10-23","kind":"disposition_to_issuer","acquired":false,"shares":3718,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock (\"Restricted Stock Unit\") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock (\"Restricted Stock Unit\") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock (\"Restricted Stock Unit\") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock (\"Restricted Stock Unit\") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3718},"source":{"system":"sec-edgar","filing":"0001104659-20-117792","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920117792/a4.xml","form_type":"4"}},{"id":3001136,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-23T17:32:04.000Z","date":"2020-10-23","kind":"disposition_to_issuer","acquired":false,"shares":6540,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6540},"source":{"system":"sec-edgar","filing":"0001104659-20-117792","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920117792/a4.xml","form_type":"4"}},{"id":3001135,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-23T17:32:04.000Z","date":"2020-10-23","kind":"disposition_to_issuer","acquired":false,"shares":49244,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the \"Offer Price\"), without interest and subject to required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the \"Offer Price\"), without interest and subject to required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-117792","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920117792/a4.xml","form_type":"4"}},{"id":3030181,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-16T18:43:43.000Z","date":"2020-09-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 20, 2019. The Reporting Person exercised no discretion with respect to these transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shares vested and became exercisable in 16 quarterly installments from May 10, 2016."}],"balance_after":34271,"derivative":{"exercise_price":4.21,"expiration_date":"2026-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001640455-20-000116","document":"wf-form4_160029620899164.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000116/wf-form4_160029620899164.xml","form_type":"4"}},{"id":3030180,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-16T18:43:43.000Z","date":"2020-09-15","kind":"sale","acquired":false,"shares":5000,"price":10.5,"value":52500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 20, 2019. The Reporting Person exercised no discretion with respect to these transactions."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001640455-20-000116","document":"wf-form4_160029620899164.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000116/wf-form4_160029620899164.xml","form_type":"4"}},{"id":3030179,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-16T18:43:43.000Z","date":"2020-09-15","kind":"sale","acquired":false,"shares":5000,"price":9.5,"value":47500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 20, 2019. The Reporting Person exercised no discretion with respect to these transactions."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001640455-20-000116","document":"wf-form4_160029620899164.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000116/wf-form4_160029620899164.xml","form_type":"4"}},{"id":3030178,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-16T18:43:43.000Z","date":"2020-09-15","kind":"exercise","acquired":true,"shares":10000,"price":4.21,"value":42100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 20, 2019. The Reporting Person exercised no discretion with respect to these transactions."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001640455-20-000116","document":"wf-form4_160029620899164.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000116/wf-form4_160029620899164.xml","form_type":"4"}},{"id":3031882,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-09-15T16:30:41.000Z","date":"2020-09-14","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":16.96,"exercise_date":"2020-03-05","expiration_date":"2026-03-05","underlying":"Common Stock, par value $0.01 per share","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001104659-20-105255","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920105255/a4.xml","form_type":"4"}},{"id":3031881,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value per share","published_at":"2020-09-15T16:30:41.000Z","date":"2020-09-14","kind":"exercise","acquired":true,"shares":2500,"price":16.96,"value":42400.0,"ownership":{"direct":true},"balance_after":39577,"source":{"system":"sec-edgar","filing":"0001104659-20-105255","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920105255/a4.xml","form_type":"4"}},{"id":3051685,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-08-20T16:15:14.000Z","date":"2020-08-17","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":16.96,"exercise_date":"2020-03-05","expiration_date":"2026-03-05","underlying":"Common Stock, par value $0.01 per share","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-20-097230","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920097230/a4.xml","form_type":"4"}},{"id":3051684,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value per share","published_at":"2020-08-20T16:15:14.000Z","date":"2020-08-17","kind":"exercise","acquired":true,"shares":20000,"price":16.96,"value":339200.0,"ownership":{"direct":true},"balance_after":37077,"source":{"system":"sec-edgar","filing":"0001104659-20-097230","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920097230/a4.xml","form_type":"4"}},{"id":3058019,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-08-14T16:33:35.000Z","date":"2020-08-12","kind":"exercise","acquired":false,"shares":17077,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":12.93,"exercise_date":"2020-06-07","expiration_date":"2026-06-07","underlying":"Common Stock, par value $0.01 per share","underlying_shares":17077},"source":{"system":"sec-edgar","filing":"0001104659-20-095587","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920095587/a4.xml","form_type":"4"}},{"id":3058018,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value per share","published_at":"2020-08-14T16:33:35.000Z","date":"2020-08-12","kind":"exercise","acquired":true,"shares":17077,"price":12.93,"value":220805.61,"ownership":{"direct":true},"balance_after":17077,"source":{"system":"sec-edgar","filing":"0001104659-20-095587","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920095587/a4.xml","form_type":"4"}},{"id":3091889,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T19:32:38.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 filed on June 29, 2020 erroneously reported 13,550 shares of common stock subject to the stock option. This amendment is being filed to disclose the correct number of shares subject to the reported stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2021 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":15700,"derivative":{"exercise_price":7.58,"expiration_date":"2030-06-26","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-20-000085","document":"wf-form4a_159373274211305.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000085/wf-form4a_159373274211305.xml","form_type":"4/A","original_submission_date":"2020-06-29"}},{"id":3095081,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2020-07-01T21:06:52.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":144000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":144000,"derivative":{"exercise_price":1.67,"exercise_date":"2021-07-01","expiration_date":"2030-07-01","underlying":"Ordinary Shares","underlying_shares":144000},"source":{"system":"sec-edgar","filing":"0001104659-20-079782","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000110465920079782/a4.xml","form_type":"4"}},{"id":3097553,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-29T19:30:01.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":13550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2021 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":13550,"derivative":{"exercise_price":7.58,"expiration_date":"2030-06-26","underlying":"Common Stock","underlying_shares":13550},"source":{"system":"sec-edgar","filing":"0001640455-20-000069","document":"wf-form4_159347338044091.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000069/wf-form4_159347338044091.xml","form_type":"4"}},{"id":3103710,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-22T17:19:51.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":6540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2020 annual meeting of stockholders, which occurred on June 18, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer."}],"balance_after":6540,"derivative":{"exercise_price":33.62,"exercise_date":"2021-06-18","expiration_date":"2030-06-18","underlying":"Common Stock, par value $0.01 per share","underlying_shares":6540},"source":{"system":"sec-edgar","filing":"0001104659-20-075694","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920075694/a4.xml","form_type":"4"}},{"id":3103709,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value per share","published_at":"2020-06-22T17:19:51.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":3718,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2020 annual meeting of stockholders, which occurred on June 18, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer."}],"balance_after":13385,"source":{"system":"sec-edgar","filing":"0001104659-20-075694","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465920075694/a4.xml","form_type":"4"}},{"id":3118527,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-08T21:37:33.000Z","date":"2020-06-05","kind":"grant","acquired":true,"shares":13250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on June 5, 2021, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":13250,"derivative":{"exercise_price":5.29,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":13250},"source":{"system":"sec-edgar","filing":"0001209191-20-035039","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919120035039/doc4.xml","form_type":"4"}},{"id":3289125,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Purchase)","published_at":"2020-02-05T16:23:04.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":10591,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void."}],"balance_after":0,"derivative":{"exercise_price":2.84,"expiration_date":"2022-10-17","underlying":"Common Stock","underlying_shares":10591},"source":{"system":"sec-edgar","filing":"0001192482-20-000123","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000123/edgar.xml","form_type":"4"}},{"id":3289124,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:23:04.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option, which became exercisable on July 22, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":8.09,"expiration_date":"2025-07-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001192482-20-000123","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000123/edgar.xml","form_type":"4"}},{"id":3289123,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:23:04.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":4.83,"expiration_date":"2026-04-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001192482-20-000123","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000123/edgar.xml","form_type":"4"}},{"id":3289122,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:23:04.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option, which became exercisable on June 22, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":1.32,"expiration_date":"2027-06-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001192482-20-000123","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000123/edgar.xml","form_type":"4"}},{"id":3289121,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:23:04.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":1.55,"expiration_date":"2028-04-17","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001192482-20-000123","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000123/edgar.xml","form_type":"4"}},{"id":3289120,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-05T16:23:04.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":59524,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. (\"Cerecor\"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the \"Merger\").  At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001192482-20-000123","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000123/edgar.xml","form_type":"4"}},{"id":3369792,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-11-15T21:24:23.000Z","date":"2019-11-13","kind":"grant","acquired":true,"shares":7437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on November 13, 2020, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":7437,"derivative":{"exercise_price":2.43,"expiration_date":"2029-11-12","underlying":"Common Stock","underlying_shares":7437},"source":{"system":"sec-edgar","filing":"0001209191-19-056741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919119056741/doc4.xml","form_type":"4"}},{"id":3450755,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-01T21:00:16.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":5813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Amended Form 4 is being filed to correct inaccuracies with respect to the transaction date and exercise price of the stock options and reported in Table II of the Form 4 filed on June 10, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest in full on June 10, 2020, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":5813,"derivative":{"exercise_price":1.65,"expiration_date":"2029-06-09","underlying":"Common Stock","underlying_shares":5813},"source":{"system":"sec-edgar","filing":"0001209191-19-044050","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919119044050/doc4a.xml","form_type":"4/A","original_submission_date":"2019-06-10"}},{"id":3467807,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-07-03T21:00:32.000Z","date":"2019-07-02","kind":"grant","acquired":true,"shares":124000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":124000,"derivative":{"exercise_price":0.61,"exercise_date":"2020-07-02","expiration_date":"2029-07-02","underlying":"Ordinary Shares","underlying_shares":124000},"source":{"system":"sec-edgar","filing":"0001104659-19-039322","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000110465919039322/a4.xml","form_type":"4"}},{"id":3491393,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-13T10:32:14.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2020 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":15700,"derivative":{"exercise_price":4.46,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-19-000058","document":"wf-form4_156043631968154.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045519000058/wf-form4_156043631968154.xml","form_type":"4"}},{"id":3495042,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-11T16:31:15.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":17077,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2019 annual meeting of stockholders, which occurred on June 7, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer."}],"balance_after":17077,"derivative":{"exercise_price":12.93,"exercise_date":"2020-06-07","expiration_date":"2026-06-07","underlying":"Common Stock, par value $0.01 per share","underlying_shares":17077},"source":{"system":"sec-edgar","filing":"0001104659-19-034791","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465919034791/a4.xml","form_type":"4"}},{"id":3495041,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value per share","published_at":"2019-06-11T16:31:15.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":9667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2019 annual meeting of stockholders, which occurred on June 7, 2019."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer."}],"balance_after":9667,"source":{"system":"sec-edgar","filing":"0001104659-19-034791","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465919034791/a4.xml","form_type":"4"}},{"id":3495583,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-10T20:21:19.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":5813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on June 7, 2020, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":5813,"derivative":{"exercise_price":1.6,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":5813},"source":{"system":"sec-edgar","filing":"0001209191-19-035786","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919119035786/doc4.xml","form_type":"4"}},{"id":3607351,"issuer":{"id":145732,"kind":"organization","name":"IMMUNOMEDICS INC","symbol":"IMMU"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-03-07T18:40:16.000Z","date":"2019-03-05","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest in full on the first anniversary of the date of grant, provided that the reporting person remains a director on such date."}],"balance_after":22500,"derivative":{"exercise_price":16.96,"exercise_date":"2020-03-05","expiration_date":"2026-03-05","underlying":"Common Stock, par value $0.01 per share","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001104659-19-013437","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722830/000110465919013437/a4.xml","form_type":"4"}},{"id":3865483,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Purchase)","published_at":"2018-07-18T16:17:27.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option award was granted on April 17, 2018 and was subject to forfeiture if stockholder approval of a proposed amendment to the Issuer's stock incentive plan to increase the number of shares reserved for issuance under the plan was not obtained. The Issuer's stockholders approved the amendment to the Issuer's stock incentive plan at the Issuer's annual meeting of stockholders on June 14, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This amendment is being filed to amend the vesting schedule of the option award. The entire option vests and becomes exercisable on April 17, 2019, subject to the reporting person's continued service with the Issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.55,"expiration_date":"2028-04-17","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001192482-18-000340","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248218000340/edgar.xml","form_type":"4/A","original_submission_date":"2018-06-18"}},{"id":3882955,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2018-06-26T21:00:39.000Z","date":"2018-06-22","kind":"grant","acquired":true,"shares":158233,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP1.65 based on an exchange rate of $U.S. 1.3250 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":158233,"derivative":{"exercise_price":2.18,"exercise_date":"2019-06-22","expiration_date":"2028-06-22","underlying":"Ordinary Shares","underlying_shares":158233},"source":{"system":"sec-edgar","filing":"0001104659-18-042319","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000110465918042319/a4.xml","form_type":"4"}},{"id":3886140,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-21T17:15:28.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":13550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":13550,"derivative":{"exercise_price":7.92,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":13550},"source":{"system":"sec-edgar","filing":"0001640455-18-000083","document":"wf-form4_152961571214429.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000083/wf-form4_152961571214429.xml","form_type":"4"}},{"id":3890950,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Purchase)","published_at":"2018-06-18T16:16:30.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option award was granted on April 17, 2018 and was subject to forfeiture if stockholder approval of a proposed amendment to the Issuer's stock incentive plan to increase the number of shares reserved for issuance under the plan was not obtained. The Issuer's stockholders approved the amendment to the Issuer's stock incentive plan at the Issuer's annual meeting of stockholders on June 14, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on April 17, 2019, then in 24 equal monthly installments on the 17th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.55,"expiration_date":"2028-04-17","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001192482-18-000297","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248218000297/edgar.xml","form_type":"4"}},{"id":3899865,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-08T21:41:55.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":5813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on June 7, 2019, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":5813,"derivative":{"exercise_price":8.12,"expiration_date":"2028-06-06","underlying":"Common Stock","underlying_shares":5813},"source":{"system":"sec-edgar","filing":"0001209191-18-036748","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919118036748/doc4.xml","form_type":"4"}},{"id":3989705,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-19T18:42:03.000Z","date":"2018-03-15","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shares vest and become exercisable in 16 quarterly installments from May 10, 2016."}],"balance_after":44271,"derivative":{"exercise_price":4.21,"expiration_date":"2026-05-09","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001640455-18-000043","document":"wf-form4_152149930973105.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000043/wf-form4_152149930973105.xml","form_type":"4"}},{"id":3989704,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-19T18:42:03.000Z","date":"2018-03-15","kind":"sale","acquired":false,"shares":2000,"price":28.11,"value":56220.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001640455-18-000043","document":"wf-form4_152149930973105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000043/wf-form4_152149930973105.xml","form_type":"4"}},{"id":3989703,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-19T18:42:03.000Z","date":"2018-03-15","kind":"exercise","acquired":true,"shares":2000,"price":4.21,"value":8420.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001640455-18-000043","document":"wf-form4_152149930973105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000043/wf-form4_152149930973105.xml","form_type":"4"}},{"id":4086587,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-29T20:26:32.000Z","date":"2018-01-26","kind":"exercise","acquired":false,"shares":4000,"price":4.21,"value":16840.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option, representing the right to purchase a total of 50,271 shares of common stock, vests in 16 equal quarterly installments following May 10, 2016."}],"balance_after":46271,"derivative":{"exercise_price":4.21,"expiration_date":"2026-05-09","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001640455-18-000007","document":"wf-form4_151727557738985.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000007/wf-form4_151727557738985.xml","form_type":"4"}},{"id":4086586,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-29T20:26:32.000Z","date":"2018-01-26","kind":"sale","acquired":false,"shares":4000,"price":25,"value":100000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to the trade."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001640455-18-000007","document":"wf-form4_151727557738985.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000007/wf-form4_151727557738985.xml","form_type":"4"}},{"id":4086585,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-29T20:26:32.000Z","date":"2018-01-26","kind":"exercise","acquired":true,"shares":4000,"price":4.21,"value":16840.0,"ownership":{"direct":true},"balance_after":4000,"source":{"system":"sec-edgar","filing":"0001640455-18-000007","document":"wf-form4_151727557738985.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000007/wf-form4_151727557738985.xml","form_type":"4"}},{"id":4184114,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2017-10-18T16:16:54.000Z","date":"2017-10-17","kind":"purchase","acquired":true,"shares":10591,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10591,"derivative":{"exercise_price":2.84,"exercise_date":"2017-10-17","expiration_date":"2022-10-17","underlying":"Common Stock","underlying_shares":10591},"source":{"system":"sec-edgar","filing":"0001144204-17-053029","document":"tv477168_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000114420417053029/tv477168_4.xml","form_type":"4"}},{"id":4184113,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-18T16:16:54.000Z","date":"2017-10-17","kind":"purchase","acquired":true,"shares":59524,"price":1.26,"value":75000.24,"ownership":{"direct":true},"balance_after":59524,"source":{"system":"sec-edgar","filing":"0001144204-17-053029","document":"tv477168_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000114420417053029/tv477168_4.xml","form_type":"4"}}],"next_cursor":"2017-10-18T16:16:54.000000Z,4184113"}